Key Points
- Stan Smith purchased 15,000 MAIA shares on Nov. 25 at $0.98 each (total $14,700), raising his holdings to 1,349,289 shares (~$1.32M) — a 1.12% increase; the trade was filed in an SEC Form 4.
- Insider buying continued: Smith also bought 10,000 shares on Nov. 24 at $0.99 and 19,230 shares on Oct. 1 at $1.30, indicating repeated purchases by the director.
- MAIA stock traded at $1.06 midday, sits in a 52-week range of $0.87–$2.74, has a market cap of about $39.3M, and only ~5.65% of shares are held by institutional investors.
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Stan Smith purchased 15,000 shares of the stock in a transaction dated Tuesday, November 25th. The stock was acquired at an average cost of $0.98 per share, for a total transaction of $14,700.00. Following the transaction, the director owned 1,349,289 shares of the company's stock, valued at approximately $1,322,303.22. This trade represents a 1.12% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Stan Smith also recently made the following trade(s):
- On Monday, November 24th, Stan Smith acquired 10,000 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $0.99 per share, with a total value of $9,900.00.
- On Wednesday, October 1st, Stan Smith acquired 19,230 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.30 per share, with a total value of $24,999.00.
MAIA Biotechnology Stock Performance
MAIA stock traded up $0.09 during midday trading on Thursday, reaching $1.06. 382,828 shares of the company's stock traded hands, compared to its average volume of 224,746. The company has a 50-day moving average price of $1.35 and a two-hundred day moving average price of $1.57. MAIA Biotechnology, Inc. has a 52 week low of $0.87 and a 52 week high of $2.74. The firm has a market capitalization of $39.25 million, a PE ratio of -1.45 and a beta of -0.01.
Institutional Trading of MAIA Biotechnology
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Centric Wealth Management lifted its holdings in MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company's stock worth $1,032,000 after purchasing an additional 505,150 shares in the last quarter. Geode Capital Management LLC increased its position in shares of MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after buying an additional 7,746 shares during the period. Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology during the second quarter valued at about $52,000. Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology during the second quarter valued at about $29,000. Finally, Centerpoint Advisory Group purchased a new stake in shares of MAIA Biotechnology in the second quarter worth about $28,000. 5.65% of the stock is currently owned by institutional investors.
MAIA Biotechnology Company Profile
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
